SEC Form 3 · accession 0001209191-16-133330
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott W Morrison
Director
Period of report
Jul 19, 2016
Accepted (ET)
Jul 19, 2016 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| No securities beneficially held | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.50 | holding | — | — | — | — | Dec 26, 2025 | Common Stock | 33,635 | — | D |
Explanation of responses
- F1The option vests as to 8.333% of the total shares quarterly, beginning March 26, 2016, with 100% of the total shares vested and exercisable on December 26, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting upon a change of control of the issuer.